Treatment-Resistance to Clozapine in Association With Ultrarapid CYP1A2 Activity and the C → A Polymorphism in Intron 1 of the CYP1A2 Gene: Effect of Grapefruit Juice and Low-Dose Fluvoxamine
- 1 December 2001
- journal article
- case report
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 21 (6) , 603-607
- https://doi.org/10.1097/00004714-200112000-00011
Abstract
Antipsychotic response to clozapine varies markedly among patients with schizophrenia. The disposition of clozapine is dependent, in part, on the cytochrome P-450 (CYP) 1A2 enzyme in vivo. In theory, a very high CYP1A2 activity may lead to subtherapeutic concentrations and treatment resistance to clozapine. This prospective case study evaluates the clinical significance of ultrarapid CYP1A2 activity and a recently discovered single nucleotide (C → A) polymorphism in intron 1 of the CYP1A2 gene (CYP1A2*F) for treatment resistance to clozapine. In addition, we describe the effect of grapefruit juice or low-dose fluvoxamine (25–50 mg/d) coadministration on clozapine and active metabolite norclozapine steady-state plasma concentration and antipsychotic response.Keywords
This publication has 27 references indexed in Scilit:
- CYP1A2 Activity as Measured by a Caffeine Test Predicts Clozapine and Active Metabolite Norclozapine Steady-State Concentration in Patients With SchizophreniaJournal of Clinical Psychopharmacology, 2001
- Pharmacogenetic prediction of clozapine responseThe Lancet, 2000
- Genetics and etiology of schizophrenia and bipolar disorderBiological Psychiatry, 2000
- Pharmacogenetics of antipsychotic treatment: lessons learned from clozapineBiological Psychiatry, 2000
- Neurotransmitter-related genes and antipsychotic response: pharmacogenetics meets psychiatric treatment.Annals of Medicine, 2000
- Cytochrome P450 and therapeutic drug monitoring with respect to clozapineEuropean Neuropsychopharmacology, 1999
- Treatment of schizophrenia and spectrum disorders: pharmacotherapy, psychosocial treatments, and neurotransmitter interactionsBiological Psychiatry, 1999
- Pharmacologic treatment of schizophreniaBiological Psychiatry, 1999
- Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test.British Journal of Clinical Pharmacology, 1994
- ClozapineNew England Journal of Medicine, 1991